Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3PS2E)

• Drug Name: Squalamine Drug Info
• Synonyms: Squalamine; 148717-90-2; Squalamine [INN]; UNII-F8PO54Z4V7; F8PO54Z4V7; CHEBI:80765; 3beta-N-1-(N-(3-(4-Aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate; (3beta,5alpha,7alpha,24R)-3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate); 3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-; Cholestane-7,24-diol, 3-((3-(4-(aminobutyl)amino)propyl)amio)-, 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 3	[1]
Diabetic macular edema	9B71.02	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 72495
  ChEBI ID: CHEBI:80765
  CAS Number: CAS 148717-90-2
  TTD Drug ID: DM3PS2E

Molecule-Related Drug Atlas

Drug(s) Targeting Fibroblast growth factor-2 (FGF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sucralfate	DMP9HBO	Acne vulgaris	ED80	Approved	[4]
DVC1-0101	DMUGBQK	Arteriosclerosis	BD40	Phase 2	[5]
Bemarituzumab	DMWNYIE	Gastric adenocarcinoma	2B72	Phase 2	[6]
FPA144	DM1EBRK	Bladder cancer	2C94	Phase 1	[7]
TGP-580	DMYN6G0	Neurodegenerative disorder	8A20-8A23	Discontinued in Phase 2	[8]
RG-8803	DMI0CYV	Diabetic retinopathy	9B71.0	Terminated	[9]
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[10]
N,O6-Disulfo-Glucosamine	DMYCV7U	Discovery agent	N.A.	Investigative	[10]
BIBF100	DMUWO6D	Multiple myeloma	2A83	Investigative	[11]
1,4-Dideoxy-O2-Sulfo-Glucuronic Acid	DM9KUQZ	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Vascular endothelial growth factor (VEGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[12]
PF-06439535	DMVHZDP	Non-small-cell lung cancer	2C25.Y	Phase 3	[13]
M710	DM1PRT6	Diabetic macular edema	9B71.02	Phase 3	[14]
FKB238	DM6R2XF	Non-small-cell lung cancer	2C25.Y	Phase 3	[15]
KSI-301	DMM2LTC	Diabetic macular edema	9B71.02	Phase 3	[16]
TRS003	DMM1VOH	Colorectal cancer	2B91.Z	Phase 3	[17]
MYL-1402O	DMXN2PP	Non-small-cell lung cancer	2C25	Phase 3	[18]
SB15	DMTOS6C	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[19]
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
ALG-1001	DMR2YPF	Diabetic macular edema	9B71.02	Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor-2 (FGF2)	TTGKIED	FGF2_HUMAN	Modulator	[3]
Platelet-derived growth factor A (PDGFA)	TTSM78N	PDGFA_HUMAN	Inhibitor	[2]
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN	Modulator	[3]

References

• [1] ClinicalTrials.gov (NCT00139282) A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
• [4] Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
• [5] DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
• [9] US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [12] Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
• [13] National Cancer Institute Drug Dictionary (drug id 43234).
• [14] ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of Fujifilm.
• [16] Clinical pipeline report, company report or official report of Kodiak Sciences.
• [17] Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
• [18] MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
• [19] Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.
• [20] Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
• [21] Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.